Anxiety treatment for Fort Lauderdale — SSRI dosing done right, CBT that works.

RECO Integrated Psychiatry sits 40 minutes up I-95 from Las Olas — close enough that Fort Lauderdale patients keep weekly follow-ups through SSRI titration and biweekly appointments once stable. The anxiety protocol is specific: DSM-5-TR primary diagnosis at intake using GAD-7, PDSS, LSAS, and Y-BOCS; SSRIs titrated to anxiety-appropriate target doses; buspirone, low-dose aripiprazole, or beta-blocker augmentation matched to the disorder rather than layered by default; and CBT referrals to therapists who deliver ERP, interoceptive exposure, or in-vivo exposure as the diagnosis requires.

From Las Olas, Victoria Park, and Coral Ridge, the drive to RECO Integrated Psychiatry’s Delray Beach office runs 26 miles up I-95 — roughly 40 minutes off-peak, and manageable for the weekly medication follow-ups most Fort Lauderdale patients need during SSRI titration. Anxiety disorders account for the largest single share of outpatient psychiatric referrals in Broward County, and the treatment that produces remission is more specific — and more technical — than a starter SSRI dose written during a primary care visit.

The disorder distinctions that change treatment

Generalized anxiety disorder, panic disorder, social anxiety disorder, and obsessive-compulsive disorder are all filed under “anxiety” in casual conversation and in many rushed primary care encounters. Clinically they behave differently. GAD responds to SSRI or SNRI monotherapy at the upper end of the dose range plus CBT with worry exposure. Panic disorder requires interoceptive exposure — deliberate reproduction of the somatic sensations the patient fears — which no other anxiety protocol emphasizes. Social anxiety responds to in-vivo exposure and, for the performance subtype, low-dose beta-blocker. OCD requires exposure and response prevention (ERP), a distinct CBT protocol whose local therapist supply is limited.

RECO’s intake battery includes the GAD-7 for generalized anxiety, the Panic Disorder Severity Scale (PDSS), the Liebowitz Social Anxiety Scale (LSAS), and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The intake note names the DSM-5-TR primary diagnosis, not a generic “anxiety” label, so downstream therapy referrals route to the correct protocol.

Comorbid anxiety disorders are the rule rather than the exception — GAD with panic, OCD with social anxiety, panic with agoraphobia, any of the above with a major depressive episode. The treatment plan sequences them by severity and functional impact, not by which one the patient described first.

SSRI dosing for anxiety versus depression

Effective SSRI doses for anxiety disorders sit at the upper end of the range used for depression, and the most common failure point in outpatient anxiety treatment is under-dosing. Target ranges: sertraline 150-200 mg for GAD or OCD, escitalopram 20 mg, paroxetine 40-60 mg, and fluoxetine 40-80 mg for OCD. A patient who has been on sertraline 50 mg for six months without response has not failed sertraline — the trial is incomplete.

Anxious patients are typically started at half the usual starting dose (sertraline 12.5-25 mg, escitalopram 5 mg) because SSRI-associated activation on initiation can worsen anxiety and drive early self-discontinuation. Titration is slower, with follow-up spacing designed to catch activation before the patient stops the medication independently. The target window is higher.

SNRIs — venlafaxine XR 150-225 mg, duloxetine 60-120 mg — are second-line for GAD and reasonable first-line where comorbid depression or chronic pain shifts the calculus. Bupropion is generally avoided as monotherapy in anxious presentations because of its activating profile.

Augmentation and second-line options

Partial responders to first-line SSRI in GAD are augmented with buspirone 20-60 mg/day in divided dosing — the combination has evidence and buspirone carries no dependence risk. Panic disorder partial responders benefit more from adding CBT with interoceptive exposure than from further medication augmentation; the ceiling for pharmacologic response in panic is reached earlier than in GAD.

OCD partial responders are augmented with low-dose aripiprazole (2-5 mg) or risperidone (0.5-2 mg). The evidence for antipsychotic augmentation in OCD is stronger than for cross-switching between SSRIs, which is a common misstep. Clomipramine remains an option when SSRIs and augmentation fail, with attention to baseline ECG and anticholinergic burden.

Propranolol 10-40 mg given 45-60 minutes pre-event has a defined role in situational performance anxiety and does not treat generalized states. Hydroxyzine 25-50 mg and gabapentin 300-900 mg cover PRN and short-window needs without the benzodiazepine risk profile. RECO’s anxiety treatment program matches augmentation to the disorder rather than layering agents by default.

Benzodiazepines — when we do and don’t prescribe

Benzodiazepines have a legitimate but narrow role: short-term crisis management within a defined two-to-four-week window during SSRI onset, and select cases of panic disorder refractory to adequate SSRI trials plus CBT. They are not maintenance treatment for chronic anxiety in the outpatient setting.

The clinical argument against routine long-term use is not moral. Benzodiazepines blunt the extinction learning that drives CBT response, which means a patient on standing alprazolam is less likely to benefit from the exposure work they are simultaneously paying for. They carry dependence risk, dose escalation over time, and cognitive effects that compound in patients over 60. For anyone with a personal or family history of alcohol or sedative use disorder, RECO’s default is not to prescribe.

When benzodiazepines are prescribed, the plan is written with a taper timeline and specified non-benzodiazepine alternatives — hydroxyzine or gabapentin for baseline anxiety, propranolol for situational use. Open-ended monthly refills without a taper plan are not part of the practice.

What the first visit actually covers

The initial evaluation runs 60-90 minutes. History includes symptom onset, prior medication trials with actual doses and durations, therapy history (and whether the therapy delivered was structured CBT or supportive counseling), family psychiatric history, medical comorbidity, and a substance use screen. Relevant scales — GAD-7, PDSS, LSAS, Y-BOCS, PHQ-9 for comorbid depression, ASRS where attentional symptoms are prominent — are administered at intake and repeated at follow-ups to track response numerically.

The visit ends with a written treatment plan: DSM-5-TR primary diagnosis, medication choice with target dose and titration schedule, CBT protocol recommendation with a named referral list, and follow-up cadence. Fort Lauderdale patients typically follow up in two weeks after initiation, then every four to six weeks through target-dose achievement, then every two to three months for maintenance.

Insurance and admissions from Fort Lauderdale

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield plans. Coverage for outpatient psychiatric evaluation and medication management is standard across these carriers; TMS and Spravato carry separate prior-authorization requirements that admissions handles before the first treatment session.

For patients in Las Olas, Victoria Park, Coral Ridge, Rio Vista, and Wilton Manors, the logistics are straightforward: the initial evaluation is in person at the Delray Beach office, and medication management follow-ups can move to telepsychiatry once the treatment relationship is established. TMS courses require in-person attendance five days a week for approximately six weeks — a schedule most Broward County patients organize around morning appointments ahead of I-95 southbound congestion.

Serving residents of: Las Olas, Victoria Park, Coral Ridge, Rio Vista, Wilton Manors.